BACKGROUND: The HIVNET 012 trial in Uganda demonstrated that single-dose nevirapine (NVP) can prevent HIV-1 mother-to-child transmission. NVP resistance (NVPR) mutations were detected in 25% of women 6 to 8 weeks after NVP, with a higher rate of NVPR in women with subtype D than A. This study examined emergence and fading of specific NVPR mutations in women with these subtypes. METHODS: Plasma HIV-1 was analyzed with the ViroSeq genotyping system (Celera Diagnostics, Alameda, CA). Genotypes were obtained from paired samples collected 7 days and 6 to 8 weeks after NVP from 140 women, 83 with subtype A and 57 with subtype D. RESULTS: The rate of NVPR was similar in women with subtype A vs. D at 7 days but was higher in subtype D than A at 6 to 8 weeks. The higher rate of NVPR in subtype D was explained by at least 2 factors: Y181C faded from detection at a greater rate in women with subtype A (odds ratio = 3.06; 95% CI, 1.04, 8.90) and K103N accumulated at a greater rate in women with subtype D (odds ratio = 1.74; 95% CI, 0.62, 4.87). CONCLUSIONS: HIV-1 subtype influences selection and fading of HIV-1 variants with specific drug resistance mutations after antiretroviral drug exposure.
BACKGROUND: The HIVNET 012 trial in Uganda demonstrated that single-dose nevirapine (NVP) can prevent HIV-1 mother-to-child transmission. NVP resistance (NVPR) mutations were detected in 25% of women 6 to 8 weeks after NVP, with a higher rate of NVPR in women with subtype D than A. This study examined emergence and fading of specific NVPR mutations in women with these subtypes. METHODS: Plasma HIV-1 was analyzed with the ViroSeq genotyping system (Celera Diagnostics, Alameda, CA). Genotypes were obtained from paired samples collected 7 days and 6 to 8 weeks after NVP from 140 women, 83 with subtype A and 57 with subtype D. RESULTS: The rate of NVPR was similar in women with subtype A vs. D at 7 days but was higher in subtype D than A at 6 to 8 weeks. The higher rate of NVPR in subtype D was explained by at least 2 factors: Y181C faded from detection at a greater rate in women with subtype A (odds ratio = 3.06; 95% CI, 1.04, 8.90) and K103N accumulated at a greater rate in women with subtype D (odds ratio = 1.74; 95% CI, 0.62, 4.87). CONCLUSIONS:HIV-1 subtype influences selection and fading of HIV-1 variants with specific drug resistance mutations after antiretroviral drug exposure.
Authors: Jessica Fogel; Donald R Hoover; Jin Sun; Lynne M Mofenson; Mary G Fowler; Allan W Taylor; Newton Kumwenda; Taha E Taha; Susan H Eshleman Journal: AIDS Date: 2011-04-24 Impact factor: 4.177
Authors: Dara A Lehman; Dalton C Wamalwa; Connor O McCoy; Frederick A Matsen; Agnes Langat; Bhavna H Chohan; Sarah Benki-Nugent; Rebecca Custers-Allen; Frederic D Bushman; Grace C John-Stewart; Julie Overbaugh Journal: J Acquir Immune Defic Syndr Date: 2012-07-01 Impact factor: 3.731
Authors: Shahin Lockman; Michael D Hughes; James McIntyre; Yu Zheng; Tsungai Chipato; Francesca Conradie; Fred Sawe; Aida Asmelash; Mina C Hosseinipour; Lerato Mohapi; Elizabeth Stringer; Rosie Mngqibisa; Abraham Siika; Diana Atwine; James Hakim; Douglas Shaffer; Cecilia Kanyama; Kara Wools-Kaloustian; Robert A Salata; Evelyn Hogg; Beverly Alston-Smith; Ann Walawander; Eva Purcelle-Smith; Susan Eshleman; James Rooney; Sibtain Rahim; John W Mellors; Robert T Schooley; Judith S Currier Journal: N Engl J Med Date: 2010-10-14 Impact factor: 91.245
Authors: Dara A Lehman; Michael H Chung; Jennifer M Mabuka; Grace C John-Stewart; James Kiarie; John Kinuthia; Julie Overbaugh Journal: J Acquir Immune Defic Syndr Date: 2009-08-15 Impact factor: 3.731
Authors: Jeffrey S A Stringer; Michelle S McConnell; James Kiarie; Omotayo Bolu; Thanomsak Anekthananon; Tavatchai Jariyasethpong; Dara Potter; Winnie Mutsotso; Craig B Borkowf; Dorothy Mbori-Ngacha; Peter Muiruri; John Odero Ong'ech; Isaac Zulu; Lungowe Njobvu; Bongkoch Jetsawang; Sonal Pathak; Marc Bulterys; Nathan Shaffer; Paul J Weidle Journal: PLoS Med Date: 2010-02-16 Impact factor: 11.069
Authors: Megan Wind-Rotolo; Christine Durand; Lisa Cranmer; Alison Reid; Neil Martinson; Meg Doherty; Benjamin L Jilek; Joseph Kagaayi; Allan Kizza; Visva Pillay; Oliver Laeyendecker; Steven J Reynolds; Susan H Eshleman; Bryan Lau; Stuart C Ray; Janet D Siliciano; Thomas C Quinn; Robert F Siliciano Journal: J Infect Dis Date: 2009-05-01 Impact factor: 5.226